SCHEMBL7579745

SCHEMBL7579745

COC(=O)c1cc(C)c(Cl)nc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
MAPT P10636 1/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KDM4E B2RXH2 3/20 0.44
ABL1 P00519 1/20 0.42
ACHE P22303 3/20 0.41
CYP46A1 Q9Y6A2 1/20 0.41
NQO2 P16083 4/20 0.40
GAA P10253 2/20 0.40
RXFP1 Q9HBX9 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
ALDH1A1 P00352 2/20 0.40
CASP3 P42574 1/20 0.40
SENP8 Q96LD8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20302447 0.87 ACHE (0.49) SMN1; SMN2NPC1RAB9AMAPTNFKB1
SCHEMBL20298363 0.86 KDM4E (0.42) SMN1; SMN2NPC1RAB9AMAPTNFKB1
SCHEMBL19023139 0.84 ACHE (0.41) SMN1; SMN2NPC1RAB9AMAPTNFKB1
SCHEMBL19037342 0.84 KDM4E (0.47) SMN1; SMN2NPC1RAB9AMAPTNFKB1
SCHEMBL20298364 0.84 GAA (0.47) SMN1; SMN2NPC1RAB9AMAPTNFKB1
SCHEMBL22833387 0.83 GAA (0.49) SMN1; SMN2NPC1RAB9AMAPTNFKB1
SCHEMBL20298317 0.83 KDM4E (0.40) SMN1; SMN2NPC1RAB9AMAPTNFKB1
SCHEMBL25501785 0.83 KDM4E (0.40) SMN1; SMN2NPC1RAB9AMAPTNFKB1
SCHEMBL20560379 0.82 CASP1 (0.54) SMN1; SMN2MAPTL3MBTL1KDM4EACHE
SCHEMBL20298328 0.82 KDM4E (0.39) SMN1; SMN2NPC1RAB9AMAPTNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025007784-A1 HETEROAROMATIC RING COMPOUND, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2025-01-09 WO disclosed
CN-112574199-B Heterocyclic compounds as Kras-G12C inhibitors 首药控股(北京)股份有限公司 2021-05-18 CN disclosed
CN-112574199-A Heterocyclic compounds as Kras-G12C inhibitors 首药控股(北京)股份有限公司 2021-03-30 CN disclosed
US-20020049223-A1 Quinoline and naphthyridine carboxylic acid antibacterials ABBOTT LABORATORIES 2002-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049223-A1 Quinoline and naphthyridine carboxylic acid antibacterials NQO2, NQO1, NDUFA7 SMN1; SMN2 3221/4885NPC1 215/4885RAB9A 794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.